Genmab — Oktober 2018

[gentogen]

Regarding 9:14. Only 5 locations (in three countries) are recruiting so most likely 'primary completion' date is not correct. At least my guess would be that they are not that far

[E_L]

yes, that confused me also, unless those 5 locations recruited very fast & enough patients to say something? we'll see

[JStudsgaard]

Is it a potential question for the Q&A or is this purely on JNJ?

[E_L]

you can try; maybe Jan is in a good mood

[Helge_LarsenPI-redaktør]

Just a moment...

(www.proinvestor.com)

[jkj]

El do you have a link to find ESMO abstrakts

[E_L]

here somewhere https://www.esmo.org/Conferences/ESMO-2018-Congress/Abstracts

[Bulder]

Helge, så er der lidt til at starte med i q&a

[jkj]

.

[Helge_LarsenPI-redaktør]

Tusinde tak Bulder. Du er skarp.

[jkj]

Ikke umiddelbart nogen orale præsentationer fra Genmab på ESMO, men de bedste præsentationer. Presidential Symposium – Oral presentations samt latebreaker er endnu ikke at se.

[gentogen]

Genmab har annonceret på deres hjemmeside, at der er tale om en poster til præsentation Date and Time: October 20, 12:30-13:30 CEST

[Plimsoller]

Test

[Bella1]

Plimsoller, andre vigtige sager skal passes, - der er "Vild med svans"!

[bongobob]

Janssen har JNJ-372 med på ESMO https://www.businesswire.com/news/home/20181010005357/en/Janssen-showcase-robust-oncology-portfolio-ESMO-2018

[bongobob]

Til info er 372 EGFRxcMet begge fra Genmab royalties >=10%

[Solsen]

Lidt data fraTesaro https://finance.yahoo.com/news/tesaro-announces-data-presentations-esmo-053000748.html

[E_L]

not sure if we posted this BMS-986253 trial in September
https://clinicaltrials.gov/ct2/show/NCT03689699 http://www.genmab.com/product-pipeline/products-in-development/humax-il8#tab1

[E_L]

This ADCT-301 AML/ALL study is completed https://clinicaltrials.gov/ct2/history/NCT02588092?A=13&B=14&C=merged

[E_L]

maybe we can get an update during ASH? they did that for the Hodgkin’s trial last year.